NO943874L - Behandling av resistant neoplasma - Google Patents

Behandling av resistant neoplasma

Info

Publication number
NO943874L
NO943874L NO943874A NO943874A NO943874L NO 943874 L NO943874 L NO 943874L NO 943874 A NO943874 A NO 943874A NO 943874 A NO943874 A NO 943874A NO 943874 L NO943874 L NO 943874L
Authority
NO
Norway
Prior art keywords
treatment
chem
resistant neoplasm
neoplasm
resistant
Prior art date
Application number
NO943874A
Other languages
English (en)
Other versions
NO943874D0 (no
Inventor
Srinivasan Chandrasekhar
Anne Hollins Dantzig
Robert Lee Shepard
James Jacob Starling
Mark Alan Winter
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO943874D0 publication Critical patent/NO943874D0/no
Publication of NO943874L publication Critical patent/NO943874L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)

Abstract

Det blir beskrevet anvendelsen av en forbindelse med formelen OCH2CH2¿R2 (D hvor R1 og R3 uavhengig av hverandre er hydrogen, 0 9 l! II -CH3, -C-CCi-Cfc-alkyl) eller -C-Ar, hvor Ar er eventuelt substituert fenyl; R2 er vagt fra gruppen bestående av pyrrolldino, heksametylenimino og piperldino; et farmasøytisk akseptabelt salt eller solvat derav, i fremstillingen av et medikament som er nyttig for hemming av angioge- nese og/eller angiogene sykdommer.
NO943874A 1993-10-15 1994-10-13 Behandling av resistant neoplasma NO943874L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13767893A 1993-10-15 1993-10-15

Publications (2)

Publication Number Publication Date
NO943874D0 NO943874D0 (no) 1994-10-13
NO943874L true NO943874L (no) 1995-04-18

Family

ID=22478575

Family Applications (1)

Application Number Title Priority Date Filing Date
NO943874A NO943874L (no) 1993-10-15 1994-10-13 Behandling av resistant neoplasma

Country Status (17)

Country Link
EP (1) EP0652004B1 (no)
JP (1) JPH07149638A (no)
KR (1) KR950010891A (no)
CN (1) CN1108094A (no)
AT (1) ATE220323T1 (no)
AU (1) AU670518B2 (no)
CA (1) CA2118096A1 (no)
CZ (1) CZ253694A3 (no)
DE (1) DE69430940T2 (no)
DK (1) DK0652004T3 (no)
ES (1) ES2179063T3 (no)
HU (1) HUT71237A (no)
IL (1) IL111287A0 (no)
NO (1) NO943874L (no)
PT (1) PT652004E (no)
RU (1) RU94037233A (no)
ZA (1) ZA948025B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441964A (en) * 1993-10-15 1995-08-15 Eli Lilly And Company Methods for inhibiting bone loss using substituted benzothiophene
ZA956988B (en) * 1994-08-22 1997-02-21 Lilly Co Eli Methods of inhibiting primary endometrial hyperplasia.
RU2161964C2 (ru) * 1994-08-22 2001-01-20 Эли Лилли Энд Компани Способ ингибирования (угнетения) эндометриального рака
JPH10505348A (ja) 1994-08-31 1998-05-26 イーライ・リリー・アンド・カンパニー 耐性腫瘍の同定および治療方法
IL115582A0 (en) * 1994-10-14 1996-01-19 Lilly Co Eli Methods for treating resistant tumors
ZA961564B (en) * 1995-02-28 1997-08-27 Lilly Co Eli Methods of inhibiting ovarian cancer.
US5843974A (en) * 1995-06-06 1998-12-01 Eli Lilly And Company Methods of inhibiting melanoma using Benzothiophenes as cytotoxic agents per se
WO1997017069A1 (en) * 1995-11-07 1997-05-15 Eli Lilly And Company Methods for treating resistant tumors
US5670523A (en) * 1996-01-29 1997-09-23 Eli Lilly And Company Methods of inhibiting musculoaponeurotic fibromatoses (desmoid tumors)
ID15917A (id) * 1996-01-29 1997-08-21 Lilly Co Eli Metode untuk menghambat tumor usus besar
KR19990082055A (ko) * 1996-01-29 1999-11-15 피터 지. 스트링거 근육건막성 섬유종증(유건종)의 억제 방법
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL122026A0 (en) * 1996-10-30 1998-03-10 Lilly Co Eli Improvements in or relating to the prophylaxis of breast cancer
US6025373A (en) * 1997-04-22 2000-02-15 Eli Lilly And Company Methods for reducing fibrinogen
US20020198235A1 (en) * 2001-05-10 2002-12-26 Cedars-Sinai Medical Center Use of benzothiopenes to treat and prevent prostate cancer
US7425565B2 (en) * 2002-05-09 2008-09-16 Cedars-Sinai Medical Center Use of benzothiopenes to treat and prevent prostate cancer
FR2873692B1 (fr) * 2004-07-29 2006-12-01 Univ Claude Bernard Lyon COMPOSITIONS CONTENANT, EN ASSOCIATION AVEC UN AGENT ANTIMICROBIEN, UN COMPOSE THIOPHENIQUE OU BENZOTHIOPHENIQUE DE FORMULE(I)PRESENTANT UNE ACTIVITE INHIBITRICE DE POMPE NorA

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes

Also Published As

Publication number Publication date
AU7578694A (en) 1995-05-04
AU670518B2 (en) 1996-07-18
ATE220323T1 (de) 2002-07-15
PT652004E (pt) 2002-10-31
IL111287A0 (en) 1994-12-29
ZA948025B (en) 1996-04-15
CA2118096A1 (en) 1995-04-16
CN1108094A (zh) 1995-09-13
KR950010891A (ko) 1995-05-15
JPH07149638A (ja) 1995-06-13
CZ253694A3 (en) 1995-05-17
EP0652004A1 (en) 1995-05-10
DE69430940T2 (de) 2003-04-03
EP0652004B1 (en) 2002-07-10
DK0652004T3 (da) 2002-09-02
HUT71237A (en) 1995-11-28
HU9402961D0 (en) 1995-02-28
RU94037233A (ru) 1996-08-27
DE69430940D1 (de) 2002-08-14
NO943874D0 (no) 1994-10-13
ES2179063T3 (es) 2003-01-16

Similar Documents

Publication Publication Date Title
ATE150308T1 (de) Hemmung von thrombin
NO943874D0 (no) Behandling av resistant neoplasma
NO943879L (no) Hemming av endometriose
NO943878D0 (no) Hemming av uterinfibrose
DE69402165D1 (de) Hemmung von Seborrhoe und Akne
NO943873D0 (no) Hemming av bruskdegradering
DE69427807T2 (de) Hemmung von Hirsutismus und Alopecia bei Frauen